Naltrexone FDA Link Generic

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Also Known As:

ReVia; Antaxone; Celupan; EN-1639A; Nalorex; Naltrexone Hydrochloride; Nemexin; Trexan; EN 1639A; EN1639A; Morphinan-6-one, 17- (cyclopropylmethyl)- 4,5- epoxy- 3,14- dihydroxy- , (5alpha)-

Pharmalogical Action Categories:

Narcotic Antagonists

Heterocyclic Compounds: 207
- Alkaloids: 5592
  - Opiate Alkaloids: 5977
    - Morphinans: 35
      - Naloxone: 6058
        Naltrexone: 2787
- Bridged-Ring Heterocyclic Compounds
  - Morphinans: 35
    - Naloxone: 6058
      - Naltrexone: 2787
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Morphinans: 35
      - Naloxone: 6058
        Naltrexone: 2787
Polycyclic Compounds: 7
- Polycyclic Aromatic Hydrocarbons: 2081
  - Phenanthrenes: 29
    - Morphinans: 35
      - Naloxone: 6058
        Naltrexone: 2787

Daniel Storm Selected Research

Daniel Storm Research Topics

Disease

Drug/Important Bio-Agent (IBA)